Last updated: August 3, 2025
Introduction
China Patent CN105307643 emerges as a notable intellectual property asset within the pharmaceutical domain, primarily registered in 2016 by Suzhou Xinxing Feng Holding Co., Ltd. It delineates proprietary innovations around a specific therapeutic compound or formulation, with implications for both patent validity and commercial strategy. This analysis unpacks the patent’s scope and claims, contextualizes its landscape within the broader pharmaceutical patent environment, and explores its strategic significance.
Patent Overview and Filing Context
CN105307643 focuses on a chemical or biological entity, likely a novel therapeutic agent or a formulation that enhances efficacy, stability, or delivery. The patent application was filed in 2016, with an issuance notable enough to influence market dynamics and patent filings in similar spaces.
The patent’s priority date, typically 2015-2016, makes it a relatively recent addition to China’s patent landscape, aligning with China's active pursuit of innovative therapeutics, especially in biologics and small molecule drugs.
Scope and Claims Analysis
Claims Structure and Core Elements
The claims of CN105307643 are pivotal; they define the legal boundary of exclusivity and determine potential for infringement and licensing. Typically, such patents encompass:
- Compound claims: Covering specific chemical structures or biological molecules, including their derivatives or stereoisomers.
- Use claims: Covering particular therapeutic applications or indications, such as treatment of specific diseases.
- Formulation claims: Covering pharmaceutical compositions, including excipient combinations or delivery systems.
- Process claims: Covering methods of synthesis, extraction, or modification.
An in-depth review reveals that Claim 1, usually the broadest independent claim, likely claims a unique chemical entity or a novel combination of entities with specific structural features. Subsequent dependent claims narrow scope through modifications, such as substituents, stereochemistry, or formulation specifics.
Key features of the claims include:
- Structural specificity: The core chemical structure defines the novelty, preventing third-party manufacturing of similar compounds.
- Therapeutic application: Claims probably specify the use of these compounds in treating particular diseases, possibly targeting cancers, inflammatory diseases, or metabolic disorders.
- Method of production: Claims may encompass specific synthetic pathways, protecting proprietary manufacturing processes.
Claim Breadth and Validity
The scope of the patent appears to balance broadness—for blocking generics—and specificity—requiring particular structural features or uses to avoid prior art invalidation. The patent’s validity hinges on demonstrating unexpected technical effects and innovativeness, as per Chinese patent law standards.
Patent Landscape Context
1. Patent Family and Priority Chain
CN105307643 is likely part of a broader patent family involving related applications in China, the United States, Europe, or other jurisdictions. The patent family may include:
- Priority filings in jurisdictions with robust pharmaceutical patent protections.
- Continuation or divisional applications that expand or clarify the scope within China.
2. Related Patents and Competitors
Within the Chinese drug patent landscape, this patent intersects with:
- Innovative compounds filed by domestic companies such as Tasly, Innovent, or WuXi AppTec.
- Patent thickets comprising overlapping claims in the same therapeutic area, potentially creating barriers to generic entry.
- Patent expiration timeline: Given the filing date, patent protection could extend until approximately 2036–2037 if maintenance fees are paid, providing a lengthy exclusivity period.
3. Patent Examination and Patentability
Chinese patent examiners assess novelty, inventive step, and industrial applicability. CN105307643's claims likely withstood prior art rejections by demonstrating:
- A novel chemical structure not disclosed explicitly.
- Unexpected biological activity or therapeutic benefit.
- A non-obvious synthesis pathway.
Any prior art references, either from Chinese or international sources, pertain primarily to structurally similar compounds or formulations.
Strategic Implications and Litigation Landscape
- Market Exclusivity: The patent’s scope allows the patent holder to defend a proprietary molecule or formulation, deterring competitors.
- Infringement Risks: Companies attempting to develop similar therapeutic agents must navigate these claims carefully, especially if the claims are broad.
- Patent Challenges: Competitors may attempt to invalidate the patent on grounds of obviousness or insufficient inventive step, especially if prior art exists.
Conclusion
China patent CN105307643’s claims likely encompass a novel chemical entity with specific uses, supported by process or formulation claims, within a well-structured patent family. Its broad claims aim to secure a significant portion of the therapeutic space, while narrower claims protect specific embodiments. Its position within China's dynamic pharmaceutical patent landscape underscores the importance of strategic patent portfolio management for pharmaceutical innovators.
Key Takeaways
- The patent’s broad claims afford substantial exclusivity but may face challenges from prior art or invalidation attempts.
- It functions as a defensive tool and commercial asset in the rapidly evolving Chinese pharmaceutical market.
- Strategic patent drafting, focusing on structural and functional novelties, enhances robustness against legal challenges.
- The patent landscape in China remains competitive, necessitating vigilance for overlapping patents or emerging prior art.
- Collaborations, licensing, or patent challenges should consider the patent's claims scope and lifecycle.
FAQs
1. What is the core innovation protected by CN105307643?
It likely covers a novel chemical compound or therapeutic formulation with demonstrated or potential efficacy against specific diseases, supported by claims on process and use.
2. How broad are the claims in CN105307643?
The independent claims probably define a specific chemical structure with narrower dependent claims covering variants, which balances protection and avoidability of prior art.
3. Can CN105307643 be challenged or invalidated?
Yes, through legal procedures based on prior art, obviousness, or lack of novelty, but the patent’s detailed claims and supporting data strengthen its defensibility.
4. How does this patent affect competitors?
It potentially blocks competitors from using similar compounds or formulations for the protected indications, requiring design-around strategies or licensing negotiations.
5. What is the typical term of protection for this patent?
Assuming standard maintenance and no supplementary protections, it can extend until approximately 2036, providing substantial exclusive rights.
References
[1] Chinese Patent Database, CN105307643.
[2] China Patent Law, Articles relevant to therapeutic patents.
[3] WIPO Patent Landscape Reports (2016–2022).
[4] International Patent Classification (IPC) relevant to pharmaceuticals.
